Current Approaches to the Treatment of Hunter Syndrome
Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is an X-linked hereditary disorder associated with a deficiency of iduronate2-sulfatase (IDS). IDS deficiency provokes the accumulation of dermatan sulfate and heparan sulfate in different tissues. Clinical manifestations of MPS II are heteroge...
Main Authors: | Ekaterina Yu. Zakharova, Elena Yu. Voskoboeva, Alla N. Semyachkina, Nato D. Vashakmadze, Amina I. Gamzatova, Svetlana V. Mikhailova, Sergey I. Kutsev |
---|---|
Format: | Article |
Language: | English |
Published: |
Paediatrician Publishers, LLC
2018-10-01
|
Series: | Pediatričeskaâ Farmakologiâ |
Subjects: | |
Online Access: | https://www.pedpharma.ru/jour/article/view/1653 |
Similar Items
-
Therapy-type related long-term outcomes in mucopolysaccaridosis type II (Hunter syndrome) – Case series
by: Mojca Zerjav Tansek, et al.
Published: (2021-09-01) -
Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry
by: Joseph Muenzer, et al.
Published: (2017-05-01) -
Results of enzyme replacement therapy in Bulgarian patients with a severe form of hunter syndrome: A 42-month follow-up
by: Avdjieva-Tzavella Daniela, et al.
Published: (2018-01-01) -
Clinical case of mucopolysaccharidosis type II (Hunter syndrome)
by: E. V. Savelieva, et al.
Published: (2021-03-01) -
Recovery of Vision following Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II, Hunter Syndrome
by: Ryutaro Yamanishi, et al.
Published: (2019-06-01)